Dr. Kang on Aprepitant for Preventing CINV in Children
Hyoung Jin Kang, MD, PhD, associate professor, Department of Pediatrics, Seoul National University, South Korea, discusses a phase III trial of aprepitant for chemotherapy-induced nausea and vomiting (CINV) in children.
Hyoung Jin Kang, MD, PhD, associate professor, Department of Pediatrics, Seoul National University, South Korea, discusses a phase III trial of aprepitant for chemotherapy-induced nausea and vomiting (CINV) in children. This study was presented at the 2014 MASCC/ISOO International Symposium.
Patients aged 12-17 undergoing emetogenic chemotherapy were randomized to receive aprepitant capsule 125 mg and ondansetron before chemotherapy (on day 1) and aprepitant capsule 80 mg (on days 2-3) or placebo (on days 1-3) plus ondansetron (on day 1). A total of 302 patients were evaluated.
Researchers concluded that the drug combination with aprepitant was well tolerated and more effective in preventing CINV. Kang says these data can be practice-changing for supportive care for pediatric patients.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
Increasing Awareness of Audiovestibular Adverse Events From Immune Checkpoint Inhibitors
July 16th 2024Oncology nurses play a critical role in identifying and managing rare audiovestibular complications associated with immune checkpoint inhibitors to prevent permanent hearing loss and improve patients' quality of life.
